1
Erlotinib Tarceva
1 1,4 5 1 6,7 1,3 1,2 1. 2. 3. 4. 5. 6. 7.“Epidermal growth factor receptor inhibitor EGFRI ”
(monoclonal antibody) cetuximab panitumumab TK (ty rosine kinase) (small-molecular inhibitor) ErlotinibGefitinib
(xerosis) (pruritus) (parony chia)
(telangiectasia) (alopecia) (trichomegaly)
“ (acneiform rash)”
60-80%
pustular/mauclopapular eruption/acne/acneiform
rash “ (eborrhoeic area)”
EGFRIs 1~3
(National Cancer Institute Common Toxicity Criteria NCI-CTC grade 3)
EGFRIs II 57erlotinib 50mg/day NSCLC NCI-CTC 1.5 1 8.5 2-3 19.6 erlotinib EGFRIs NCI-CTC EGFRIs EGFRIs 3
mild moderate severe
EGFRIs
comedones acne vulgaris
hy drocortisone
1~2.5% / clindamycin 1%
pimcrolimus 1% doxycycline 100mg BID
minocycline 100mg BID EGFRI
The Oncologist 200712 610-621 (A) (C) (E) (G) (H) (F) (D) (B) (A) (C) - (F ) (G) (H) (B) telangiectasia 3 Erlotinib Erlotinib 98 Erlotinib Tarceva 53 Erlotinib 150 mg/day 1
Erlotinib induced grade III
skin toxicity Erlotinib
100 mg/day 3 Erlotinib 50 mg/day EGFRIs Annals of Oncology 2005;16:1425-1433 EGFRIs JDOG; 2005 3:599-606
D rug C etuxim ab Cetux im ab P anitum um ab Erlotinib Tum o r type: C RC CR C R CC N S CLC Efficacy
par am eter: Res po ns e rate% M ed ian su rviv al m on ths M edian sur vival m onth s M edian P F S m on ths M ed ian s urv iv al m on ths A caneifo rm eruptio n: N on e/g rade 0 2 2.4 1.4 1.9 1.5 M ild/grad e 1 6 4.6 2.5 8.5 M od erate/grade 2 2 0 9.1 6.4 S evere/gr ade 3 2 9 1 3.2 10 .0 4.3 19 .6 CRC, colorectal carcinoma. CC, renal cell carcinoma. NSCLC, non-small cell lung cancer/carcinoma. PFS, progression-free survival. 97 1~2 (97.3.6) Erlotinib 150 mg/day ( ) Erlotinib 100 mg/day Erlotinib 50 mg/day 6 (1) 12
Tarcevagrade III skin toxicity
( ) 98 2 9 2 11 3 4 … .
